166 related articles for article (PubMed ID: 3109058)
1. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation.
Eisenberg PR; Sherman LA; Tiefenbrunn AJ; Ludbrook PA; Sobel BE; Jaffe AS
Thromb Haemost; 1987 Feb; 57(1):35-40. PubMed ID: 3109058
[TBL] [Abstract][Full Text] [Related]
2. Fibrin metabolism in patients with acute myocardial infarction during and after treatment with tissue-type plasminogen activator.
Ring ME; Butman SM; Bruck DC; Feinberg WM; Corrigan JJ
Thromb Haemost; 1988 Dec; 60(3):428-33. PubMed ID: 2976994
[TBL] [Abstract][Full Text] [Related]
3. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
4. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
[TBL] [Abstract][Full Text] [Related]
5. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
6. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
7. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Okada K; Lijnen HR; Moreau H; Vanderschueren S; Collen D
Thromb Haemost; 1996 Dec; 76(6):857-9. PubMed ID: 8972000
[TBL] [Abstract][Full Text] [Related]
8. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
9. Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system.
Eisenberg PR; Sobel BE; Jaffe AS
Circulation; 1988 Sep; 78(3):592-7. PubMed ID: 3136954
[TBL] [Abstract][Full Text] [Related]
10. Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
Thromb Haemost; 1996 Sep; 76(3):339-43. PubMed ID: 8883267
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.
Declerck PJ; Mombaerts P; Holvoet P; De Mol M; Collen D
Thromb Haemost; 1987 Dec; 58(4):1024-9. PubMed ID: 3127914
[TBL] [Abstract][Full Text] [Related]
13. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
14. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
15. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
16. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
[TBL] [Abstract][Full Text] [Related]
17. The importance of antibody specificity in measuring cross-linked fibrin degradation products by ELISA.
Eisenberg PR; Rylatt DB; Rusticali F; Ferrini D; Ottani F; Galvani M
Blood Coagul Fibrinolysis; 1997 Mar; 8(2):105-13. PubMed ID: 9518041
[TBL] [Abstract][Full Text] [Related]
18. [Tissue-type plasminogen activator].
Turazza FM; Pogna M
Medicina (Firenze); 1990; 10(1):75-8. PubMed ID: 2116566
[TBL] [Abstract][Full Text] [Related]
19. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
20. [Hemorrhagic risk in intravenously administered thrombolytic treatment in acute myocardial infarction].
Acar J; Dorent R; Vahanian A; Michel PL; Cormier B; Slama M; Cazaux P; Conard J; Verdy E; Samama M
Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():59-65. PubMed ID: 3142430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
